This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
by Zacks Equity Research
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
NERVPositive Net Change KRYSPositive Net Change VIRPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
by Zacks Equity Research
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
AMGNPositive Net Change HRTXNo Net Change MRNSPositive Net Change ARQTNegative Net Change
biotechs medical pharmaceuticals
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
by Zacks Equity Research
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
JNJPositive Net Change PFEPositive Net Change ABBVPositive Net Change ARQTNegative Net Change
biotechs medical pharmaceuticals
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
by Zacks Equity Research
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
CGENPositive Net Change ANVSPositive Net Change RPTXNo Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
by Zacks Equity Research
Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.
JNJPositive Net Change HALOPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
by Zacks Equity Research
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
CGENPositive Net Change ANVSPositive Net Change ALXONegative Net Change ANNXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
by Zacks Equity Research
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
VKTXNegative Net Change IONSPositive Net Change MDGLNegative Net Change
biotechs medical pharmaceuticals
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
by Zacks Equity Research
Ocugen's (OCGN) shares rise significantly in the year-to-date period on positive progress with its promising pipeline candidates.
NERVPositive Net Change KRYSPositive Net Change OCGNPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
BMYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
by Zacks Equity Research
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
SNYPositive Net Change BIIBPositive Net Change KRYSPositive Net Change DNLIPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
BMYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
by Sundeep Ganoria
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
by Zacks Equity Research
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
RHHBYPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
by Zacks Equity Research
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
CGENPositive Net Change NTLAPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
by Zacks Equity Research
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
GILDPositive Net Change KRYSPositive Net Change RCUSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
by Zacks Equity Research
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
SNYPositive Net Change GSKPositive Net Change PFEPositive Net Change
biotechs
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
by Zacks Equity Research
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
ABBVPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
by Zacks Equity Research
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
NVSPositive Net Change RHHBYPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
GILDPositive Net Change ABBVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
RARENegative Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
by Zacks Equity Research
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
BIIBPositive Net Change HRTXNo Net Change IONSPositive Net Change BVSNegative Net Change
biotechs
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
REGNPositive Net Change SNYPositive Net Change
biotechs medical pharmaceuticals
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
by Zacks Equity Research
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
JNJPositive Net Change HRTXNo Net Change MRNSPositive Net Change ARQTNegative Net Change
biotechs medical
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
BMYPositive Net Change NERVPositive Net Change MRNSPositive Net Change KRYSPositive Net Change
biotechs